{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-059289","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.654290+00:00","generated_at":"2026-05-18T14:56:49.957973+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kyverna Therapeutics appoints Marc Grasso as CFO; Ryan Jones moves to advisor","bullets":["Dr. Marc Grasso appointed CFO effective June 30, 2025; previously CFO of Alector (ALEC) and Kura Oncology (KURA).","Outgoing CFO Ryan Jones will serve as strategic advisor through August 8, 2025; receives severance including 9 months salary and continued vesting.","Grasso receives base salary of $510,000, sign-on bonus of $250,000, and option for 450,000 shares vesting over four years.","Grasso brings over 25 years of experience in public company finance and biotech investment banking."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-059289","json":"https://secwatch.observer/filing/0001213900-25-059289.json","markdown":"https://secwatch.observer/filing/0001213900-25-059289.md","text":"https://secwatch.observer/filing/0001213900-25-059289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000121390025059289/0001213900-25-059289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000121390025059289/ea0247451-8k_kyverna.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T14:56:49.957973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}